Cellectis
Cellectis' revenue rose 75.8% to $73 million in fiscal 2025. Its operating margin was −45.3%, up from −143.5% a year earlier. Free cash flow was −$42 million, against $20 million a year earlier. The diluted share count rose 10.7%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity.
What Cellectis does
Cellectis is a French biotechnology company that edits genes to make experimental cancer treatments. Its main products in development are CAR T-cells: immune cells engineered to find and kill cancer cells. Most such treatments are made from each patient's own cells. Cellectis instead makes them from healthy donors' cells, so that one batch could treat many patients and be stored and shipped "off the shelf." It is focused on blood cancers such as leukemia and lymphoma, and it also works on gene therapies for inherited diseases. It has no approved products.
Its lead candidate, lasme-cel, began a pivotal mid-stage trial, the kind meant to support approval, in late 2025, and a second, eti-cel, is in an earlier trial. The company also licenses its gene-editing tools, called TALEN, to other companies, among them AstraZeneca, Allogene and Iovance, which develop their own treatments and can owe Cellectis payments. AstraZeneca also became a shareholder, making an initial equity investment of $80 million in 2023.
Cellectis makes its own products for trials, at a plant in Raleigh, North Carolina, and a facility in Paris that makes raw and starting materials. At the end of 2025 it had 186 employees working in research and development. An arbitration with Servier ended part of a license for an older treatment in December 2025.
Its biggest risks, as it describes them
- It has lost money in every period since it started and may need to raise more money, which may not be available.
- Gene editing is still a new technology, which makes the time and cost of winning approval hard to predict.
- Its treatments may cause serious side effects, as other CAR T-cell therapies have, which could halt their development.
- Making its treatments is complex, and it needs a steady supply of immune cells from healthy donors.
- Its licensing deals with other drug companies may not advance or succeed.
Income statement
Cellectis lost money in fiscal 2025: a net loss of $68 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 186 | 93 | 137 | 143 | 62 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | −281.2x | −241.7x | −2.4x | −2.8x | −0.7x |
| Current ratio | 4.6x | 2.5x | — | — | — |
| Quick ratio | 4.6x | 2.5x | — | — | — |
Cash flow
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −3,515.8% | 5,446.5% | 18.5% |
| Altman Z'' | — | — | — |
| Accruals ratio | −25.6% | −16.6% | −8.0% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Pass | Fail |
| Return on assets rose | Fail | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | — | — | — |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Pass | Fail |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | — | — | — |
Compare
Put Cellectis side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Cellectis | FY25 | 75.8% | −45.3% | −57.2% | — | — | — | |
| Compugen | FY25 | 161.1% | 43.0% | 43.0% | — | — | — | Compare |
| Bicycle Therapeutics | FY25 | 105.8% | −340.4% | −347.2% | — | — | — | Compare |
| Recursion Pharmaceuticals | FY25 | 26.9% | −867.9% | −506.5% | −117.2% | — | 4 | Compare |
| AbCellera Biologics | FY25 | 160.6% | −289.0% | −231.7% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 45 | 25 | 13 | 15 | 51 | 30 | 19 | 1 | 42 | 73 |
| Revenue growth | −19.8% | −43.8% | −49.5% | 19.3% | 236.1% | −40.6% | −36.8% | −96.1% | 5,397.4% | 75.8% |
| Gross profit | — | 23 | 10 | 4 | 49 | 28 | 17 | 0 | 42 | 73 |
| Research and development | 78 | 79 | 77 | 92 | 77 | 118 | 98 | 88 | 90 | 94 |
| Operating income | −67 | −93 | −105 | −124 | −42 | −104 | −90 | −97 | −60 | −33 |
| Net income | −67 | −99 | −79 | −102 | −81 | −114 | −106 | −101 | −37 | −68 |
| Diluted EPS (US$) | −1.91 | −2.78 | −1.93 | −2.41 | −1.91 | −2.55 | −2.33 | −1.77 | −0.41 | −0.67 |
| Diluted shares (millions) | 35 | 36 | 41 | 42 | 42 | 45 | 46 | 57 | 91 | 100 |
| Cash flow | ||||||||||
| Cash from operations | −33 | −52 | −68 | −69 | −80 | −105 | −87 | −25 | 23 | −39 |
| Capital expenditure | 14 | 2 | 5 | 13 | 44 | 18 | 2 | 1 | 3 | 2 |
| Free cash flow | −46 | −55 | −73 | −82 | −124 | −123 | −90 | −26 | 20 | −42 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 59 | 50 | 37 | 27 | 10 | 12 | 6 | 5 | 3 | 6 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 255 | 256 | 452 | 340 | 241 | 186 | 93 | 137 | 143 | 62 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | — | — |
| Total assets | 331 | 333 | 501 | 468 | 470 | 382 | 261 | 334 | 384 | 325 |
| Total liabilities | 58 | 49 | 51 | 112 | 161 | 146 | 135 | 250 | 252 | 249 |
| Shareholders' equity | 273 | 265 | 409 | 315 | 284 | 221 | 118 | 85 | 131 | 76 |
| Margins and ratios | ||||||||||
| Gross margin | — | 89.6% | 78.5% | 25.0% | 96.2% | 93.9% | 90.8% | 2.4% | 100.0% | 100.0% |
| Operating margin | −150.2% | −367.8% | −825.5% | −813.4% | −82.9% | −341.0% | −467.7% | −12,887.7% | −143.5% | −45.3% |
| Net margin | −150.1% | −394.5% | −618.1% | −672.1% | −158.8% | −376.3% | −553.6% | −13,385.3% | −88.6% | −92.7% |
| Free cash flow margin | −103.6% | −217.2% | −572.2% | −540.2% | −243.5% | −405.7% | −468.8% | −3,419.7% | 49.2% | −57.2% |
| Rule of 40 (growth + FCF margin) | −123.4% | −261.0% | −621.7% | −520.9% | −7.4% | −446.2% | −505.6% | −3,515.8% | 5,446.5% | 18.5% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −24.1% | −37.0% | −23.4% | −28.2% | −27.1% | −45.2% | −62.6% | −99.7% | −34.1% | −65.3% |
| Return on assets | −19.1% | −29.9% | −18.9% | −21.1% | −17.3% | −26.8% | −33.0% | −33.9% | −10.2% | −19.1% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |